Skip to main content

iRadimed Corporation (IRMD) Stock Analysis

Buy WaitVALUE-TRAP 1/5Moderate Confidence

Healthcare · Medical Devices

Wait for pullback to $86.94. At $88.99 the A.R:R is 0.9:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $86.94 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Expensive valuation.

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI... Read more

$88.99+14.9% A.UpsideScore 5.3/10#23 of 40 Medical Devices
QualityF-score9 / 9FCF yield1.36%
IncomeYield0.92%Payout38.80%sustainable
Entry $86.94(Ma200 Sticky)Stop $80.82Target $100.30(analyst − 15%)A.R:R 0.9:1Setup A.R:R 2.1:1
Analyst target$118.00+32.6%2 analysts
$100.30our TP
$88.99price
$118.00mean
$120

Wait for pullback to $86.94. At $88.99 the A.R:R is 0.9:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $86.94 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Expensive valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Wide-moat business. Accumulate on weakness. Score 5.3/10, moderate confidence.

Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

Recent Developments — iRadimed Corporation

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
V7 flight-to-quality bonus: +0.5 (Q=8.3 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (3/4)
Risks
Expensive valuation

Key Metrics

P/E (TTM)47.7
P/E (Fwd)37.1
Mkt Cap$1.1B
EV/EBITDA36.1
Profit Mgn27.4%
ROE25.0%
Rev Growth12.6%
Beta0.91
Dividend0.92%
Rating analysts9

Quality Signals

Piotroski F9/9MoatWideCompounder

Options Flow

P/C11.00bearish
IV44%normal
Max Pain$80-10.1% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ev Ebitda
0.0
Ps
1.4
Pe
2.6
Forward Pe
2.9
Peg Ratio
4.8
Forward P/E: 37.1xPEG: 1.68Expensive valuation

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
1.2
Support Resistance
1.9
52w Position
6.6
GatesA.R:R 0.9 < 1.5@spotMomentum 4.6<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.6>=4.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 71d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
66 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $76.77Resistance $91.87

Price Targets

$81
$87
$100
A.Upside+12.7%
A.R:R0.9:1
Setup A.R:R (at entry)2.1:1

Position Sizing

ConvictionHigh conviction
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Reward/Risk 0.9:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-07-30 (71d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is IRMD stock a buy right now?

Wait for pullback to $86.94. At $88.99 the A.R:R is 0.9:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $86.94 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Expensive valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Wide-moat business. Accumulate on weakness. Target $100.30 (+12.7%), stop $80.82 (−10.1%), Setup A.R:R 2.1:1. Score 5.3/10, moderate confidence.

What is the IRMD stock price target?

Take-profit target: $100.30 (+14.9% upside). Target $100.30 (+12.7%), stop $80.82 (−10.1%), Setup A.R:R 2.1:1. Stop-loss: $80.82.

What are the risks of investing in IRMD?

Expensive valuation.

Is IRMD overvalued or undervalued?

iRadimed Corporation trades at a P/E of 47.7 (forward 37.1). TrendMatrix value score: 2.8/10. Verdict: Buy (Wait for Entry).

What do analysts say about IRMD?

9 analysts cover IRMD with a consensus score of 4.1/5. Average price target: $118.

What does iRadimed Corporation do?IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible...

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.

Related stocks: GMED (Globus Medical, Inc.) · PODD (Insulet Corporation) · LIVN (LivaNova PLC) · ATEC (Alphatec Holdings, Inc.) · ENOV (Enovis Corporation)